Download PDF
Dtsch Med Wochenschr 2004; 129(42): 2255-2260
DOI: 10.1055/s-2004-831875
Übersichten
Dermatologie / Onkologie
© Georg Thieme Verlag Stuttgart · New York

Basalzellkarzinome - Ein Überblick

Basal cell carcinoma - An overviewJ. Dissemond1 , S. Grabbe1
  • 1Klinik und Poliklinik für Dermatologie, Venerologie und Allergologie, Universitätsklinikum Essen
Further Information

Publication History

eingereicht: 10.5.2004

akzeptiert: 22.7.2004

Publication Date:
14 October 2004 (online)

Also available at
    Permissions and Reprints

Das Basalzellkarzinom ist nicht nur der häufigste nicht benigne kutane Tumor, sondern auch die weltweit am häufigsten vorkommende Neoplasie der weißen Bevölkerung und somit auch von großer interdisziplinärer Relevanz [46]. Obwohl bereits 1827 die Erstbeschreibung durch Jakob erfolgte, ist bis heute die Nomenklatur nicht einheitlich (Tab. [1]). Im deutschsprachigen Raum ist weitestgehend der von Nékám 1901 vorgeschlagene Begriff Basaliom durch den Terminus Basalzellkarzinom ersetzt worden [27]. Basalzellkarzinome zeichnen sich durch ein proliferatives lokal destruierendes Wachstum aus. Die Tendenz zur Metastasierung ist jedoch gering ausgeprägt, so dass Basalzellkarzinome als semimaligne fibroepitheliale Tumore mit Adnexcharakter bezeichnet werden [6].

Tab. 1 Synonyme Bezeichnungen des Basalzellkarzinoms. Basaliom Basalzellepitheliom Basalzellkarzinom Epithelioma basocellulare

Literatur

  • 1 Alcalay J, Freeman S E, Goldberg L H, Kripke M L, Wolf J E. Decreased excision repair of pyrimidine dimers induced in the skin of basal cell carcinoma patients by simulated solar radiation.  J Invest Dermatol. 1990;  94 502
    Google Scholar
  • 2 Asada M, Korge B, Almeida H. et al . Solid basal cell epithelioma possibly originates from the lower part of the outer root sheath.  Zbl Haut. 1991;  158 2320
    Google Scholar
  • 3 Bath F J, Bong J, Perkins W, Williams H C. Interventions for basal cell carcinoma of the skin.  Cochrane Database Syst Rev. 2003;  2 CD003412
    Google Scholar
  • 4 Blum A, Metzler G, Hofmann-Wellenhof R, Soyer H P, Garbe C, Bauer J. Correlation between dermoscopy and histopathology in pigmented and non-pigmented skin tumours.  Hautarzt. 2003;  54 279-291
    Google Scholar
  • 5 Bavinck J N, Bastiaens M T, Marugg M E. et al . Further evidence for an association of HLA-DR7 with basal cell carcinoma on the tropical island of Saba.  Arch Dermatol. 2000;  136 1019-1022
    Google Scholar
  • 6 Breuninger H, Garbe K. Basalazellkarzinom.  Hautarzt. 1998;  10 S15-19
    Google Scholar
  • 7 Calista D. Topical 1 % cidofovir for the treatment of basal cell carcinoma.  Eur J Dermatol. 2002;  12 562-564
    Google Scholar
  • 8 Czarnecki D, Lewis A, Nicholson I, Tait B. Multiple basal cell carcinomas and HLA frequencies in southern Australia.  J Am Acad Dermatol. 1991;  24 559-561
    Google Scholar
  • 9 Danopoulos E D, Danopoulou I E. Regression of liver cancer with oral urea.  Lancet. 1974;  1 132
    Google Scholar
  • 10 D’Errico M, Calcagnile A S, Corona R. et al . p53 mutations and chromosome instability in basal cell carcinomas developed at an early or late age.  Cancer Res. 1997;  57 747-752
    Google Scholar
  • 11 Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation.  N Engl J Med. 2003;  348 1681-1691
    Google Scholar
  • 12 George R, Weightman W, Russ G R, Bannister K M, Mathew T H. Acitretin for chemoprevention of non-melanoma skin cancers in renal transplant recipients.  Australas J Dermatol. 2002;  43 269-273
    Google Scholar
  • 13 Giuffrida T J, Jimenez G, Nouri K. Histologic cure of basal cell carcinoma treated with cryosurgery.  J Am Acad Dermatol. 2003;  49 483-486
    Google Scholar
  • 14 Greinert R, Volkmer B, Wende A, Voss S, Breitbart E W. Prävention von Hautkrebs. Notwendigkeit, Durchführung und Erfolg.  Hautarzt. 2003;  54 1152-1163
    Google Scholar
  • 15 Kanitakis J, Alhaj-Ibrahim L, Euvrard S, Claudy A. Basal cell carcinomas developing in solid organ transplant recipients: clinicopathologic study of 176 cases.  Arch Dermatol. 2003;  139 1133-1137
    Google Scholar
  • 16 Katiyar S K, Ahmad N, Mukhtar H. Green tea and skin.  Arch Dermatol. 2000;  136 989-994
    Google Scholar
  • 17 Kim K H, Yavel R M, Gross V L, Brody N. Intralesional Interferon alpha-2b in the Treatment of Basal Cell Carcinoma and Squamous Cell Carcinoma: Revisited.  Dermatol Surg. 2004;  30 116-120
    Google Scholar
  • 18 Kopf A. Computer analysis of 3531 basalcell carcinomas of the skin.  J Derm. 1979;  6 267-281
    Google Scholar
  • 19 Kowalzick L, Rogozinski T, Wimheuer R. et al . Intralesional recombinant interferon beta-1a in the treatment of basal cell carcinoma: results of an open-label multicentre study.  Eur J Dermatol. 2002;  12 558-561
    Google Scholar
  • 20 Kumar P, Watson S, Brain A N. et al . Incomplete excision of basal cell carcinoma: a prospective multicentre audit.  Br J Plast Surg. 2002;  55 616-622
    Google Scholar
  • 21 Lear J T, Smith A G. Basal cell carcinoma.  Postgrad Med J. 1997;  73 538-542
    Google Scholar
  • 22 Levi F, La Vecchia C, Te V C, Randimbison L, Erler G. Incidence of invasive cancers following basal cell skin cancer.  Am J Epidemiol. 1998;  147 722-726
    Google Scholar
  • 23 Marmur E S, Schmults C D, Goldberg D J. A review of laser and photodynamic therapy for the treatment of nonmelanoma skin cancer.  Dermatol Surg. 2004;  30 264-271
    Google Scholar
  • 24 Miller S J. Biology of basal cell carcinoma (Part I).  J Am Acad Dermatol. 1991;  24 1-13
    Google Scholar
  • 25 Moore J V, Allan E. Pulsed ultrasound measurements of depth and regression of basal cell carcinomas after photodynamic therapy: relationship to probability of 1-year local control.  Br J Dermatol. 2003;  149 1035-1040
    Google Scholar
  • 26 Nagore E, Grau C, Molinero J, Fortea J M. Positive margins in basal cell carcinoma: relationship to clinical features and recurrence risk. A retrospective study of 248 patients.  J Eur Acad Dermatol Venereol. 2003;  17 167-170
    Google Scholar
  • 27 Nékám L. Basalioma adenoides cysticum esete.  Orvosi Hetilap. 1901;  39 1-10
    Google Scholar
  • 28 Nickoloff B J, Qin J Z, Chaturvedi V, Bacon P, Panella J, Denning M F. Life and death signaling pathways contributing to skin cancer.  J Invest Dermatol Symp Proc. 2002;  7 27-35
    Google Scholar
  • 29 Nijsten T E, Stern R S. The increased risk of skin cancer is persistent after discontinuation of psoralen+ultraviolet A: a cohort study.  J Invest Dermatol. 2003;  121 252-258
    Google Scholar
  • 30 Peterson S R, Goldberg L H. New and emerging treatments for nonmelanomas and actinic keratoses.  J Drugs Dermatol. 2003;  2 429-432
    Google Scholar
  • 31 Pfeiffer P, Hansen O, Rose C. Systemic cytotoxic therapy of basal cell carcinoma. A review of the literature.  Eur J Cancer. 1990;  26 73-77
    Google Scholar
  • 32 Pfister R. Antibiotische Behandlung maligner epthelialer Tumoren.  Fortschr Med. 1977;  12 784-787
    Google Scholar
  • 33 Reyman F. Treatment of basal cell carcinoma of the skin with 5-Fluorouracil ointment. A 10-year follow-up study.  Dermatologica. 1979;  158 368-372
    Google Scholar
  • 34 Rhodes L E, de Rie M, Enstrom Y. et al . Photodynamic therapy using topical methyl aminolevulinate vs surgery for nodular basal cell carcinoma: results of a multicenter randomized prospective trial.  Arch Dermatol. 2004;  140 17-23
    Google Scholar
  • 35 Robins W. Chemosurgery: My 15 years of experimence.  J Dermatol Surg Oncol. 1981;  9 79-789
    Google Scholar
  • 36 Rozylo-Kalinowska I, Rozylo T K. Odontogenic keratocyst in Gorlin-Goltz syndrome.  Ann Univ Mariae Curie Sklodowska. 2002;  57 79-85
    Google Scholar
  • 37 Safai B, Good R A. Basal cell carcinoma with metastasis. Review of the literature.  Arch Pathol Lab Med. 1977;  101 327-331
    Google Scholar
  • 38 Schon M, Bong A B, Drewniok C. et al . Tumor-selective induction of apoptosis and the small-molecule immune response modifier imiquimod.  J Natl Cancer Inst. 2003;  95 1138-1149
    Google Scholar
  • 39 Seegenschmiedt M H, Oberste-Beulmann S, Lang E, Lang B, Guntrum F, Olschewski T. Strahlentherapie des Basalzellkarzinoms.  Strahlenther Onkol. 2001;  177 240-246
    Google Scholar
  • 40 Smyth I, Narang M A, Evans T. et al . Isolation and characterization of human patched 2 (PTCH2), a putative tumour suppressor gene inbasal cell carcinoma and medulloblastoma on chromosome 1p32.  Hum Mol Genet. 1999;  8 291-297
    Google Scholar
  • 41 Spates S T, Mellette J R, Fitzpatrick J. Metastatic basal cell carcinoma.  Dermatol Surg. 2003;  29 650-652
    Google Scholar
  • 42 Szeimies R M, Landthaler M. Photodynamic therapy and fluorescence diagnosis of skin cancers.  Recent Results Cancer Res. 2002;  160 240-245
    Google Scholar
  • 43 Tangrea J A, Edwards B K, Taylor P R. et al . Long-term therapy with low-dose isotretinoin for prevention of basal cell carcinoma: a multicenter clinical trial. Isotretinoin-Basal Cell Carcinoma Study Group.  J Natl Cancer Inst. 1992;  84 328-332
    Google Scholar
  • 44 Thissen M R, Neumann M H, Schouten L J. A systematic review of treatment modalities for primary basal cell carcinomas.  Arch Dermatol. 1999;  135 1177-1183
    Google Scholar
  • 45 Thomas D J, King A R, Peat B G. Excision margins for nonmelanotic skin cancer.  Plast Reconstr Surg. 2003;  2 57-63
    Google Scholar
  • 46 Tran H, Chen K, Shumack S. Epidemiology and aetiology of basal cell carcinoma.  Br J Dermatol. 2003;  149 50-52
    Google Scholar
  • 47 Van Scott E G, Reinertson R P. The modulating influence of stromal environment on epithelial cells studied in human autotransplants.  J Invest Dermatol. 1961;  39 183-189
    Google Scholar
  • 48 von Domarus H, Stevens P J. Metastatic basal cell carcinoma. Report of five cases and review of 170 cases in the literature.  J Am Acad Dermatol. 1984;  10 1043-1060
    Google Scholar
  • 49 Wallberg P, Skog E. The incidence of basal cell carcinoma in an area of Stockholm County during the period 1971 - 1980.  Acta Derm Venereol. 1991;  71 134-137
    Google Scholar
  • 50 Zeitouni N C, Oseroff A R, Shieh S. Photodynamic therapy for nonmelanoma skin cancers. Current review and update.  Mol Immunol. 2003;  39 1133-1136
    Google Scholar

Dr. med. Joachim Dissemond

Universitätsklinikum Essen, Klinik und Poliklinik für Dermatologie, Venerologie und Allergologie

Hufelandstraße 55

45122 Essen

Phone: 0201/7233894

Fax: 0201/7235935

Email: joachimdissemond@hotmail.com

      >